333 related articles for article (PubMed ID: 33394527)
1. Real-world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation-wide cohort of 125 556 patients.
Heikkinen M; Taipale H; Tanskanen A; Mittendorfer-Rutz E; Lähteenvuo M; Tiihonen J
Addiction; 2021 Aug; 116(8):1990-1998. PubMed ID: 33394527
[TBL] [Abstract][Full Text] [Related]
2. Pharmacotherapy for alcohol use disorder among adults with medical disorders in Sweden.
Månsson A; Danielsson AK; Sjöqvist H; Glatz T; Lundin A; Wallhed Finn S
Addict Sci Clin Pract; 2024 May; 19(1):41. PubMed ID: 38764075
[TBL] [Abstract][Full Text] [Related]
3. Disparities in pharmacotherapy for alcohol use disorder in the context of universal health care: a Swedish register study.
Karriker-Jaffe KJ; Ji J; Sundquist J; Kendler KS; Sundquist K
Addiction; 2017 Aug; 112(8):1386-1394. PubMed ID: 28406579
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological Treatment of Alcohol use Disorder in Patients with Psychotic Disorders: A Systematic Review.
Rosenstand NJ; Nielsen AS; Skøt L; Anhøj S; Nielsen DG; Højlund M; Mellentin AI
Curr Neuropharmacol; 2024; 22(6):1129-1143. PubMed ID: 36582063
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate.
Palpacuer C; Duprez R; Huneau A; Locher C; Boussageon R; Laviolle B; Naudet F
Addiction; 2018 Feb; 113(2):220-237. PubMed ID: 28940866
[TBL] [Abstract][Full Text] [Related]
6. Medication Development for Alcohol Use Disorder: A Focus on Clinical Studies.
Leggio L; Falk DE; Ryan ML; Fertig J; Litten RZ
Handb Exp Pharmacol; 2020; 258():443-462. PubMed ID: 31628604
[TBL] [Abstract][Full Text] [Related]
7. Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France.
Chaignot C; Zureik M; Rey G; Dray-Spira R; Coste J; Weill A
Pharmacoepidemiol Drug Saf; 2018 Nov; 27(11):1239-1248. PubMed ID: 30251424
[TBL] [Abstract][Full Text] [Related]
8. Strategies to increase implementation of pharmacotherapy for alcohol use disorders: a structured review of care delivery and implementation interventions.
Williams EC; Matson TE; Harris AHS
Addict Sci Clin Pract; 2019 Feb; 14(1):6. PubMed ID: 30744686
[TBL] [Abstract][Full Text] [Related]
9. Impact of policy changes and drug shortages on acamprosate and naltrexone use in Ontario, Canada.
Konstantelos N; Tourchian N; McCormack D; Lecce P; Tadrous M; Gomes T
Drug Alcohol Depend; 2023 Jan; 242():109705. PubMed ID: 36463765
[TBL] [Abstract][Full Text] [Related]
10. Advances in Pharmacotherapy Development: Human Clinical Studies.
Litten RZ; Falk DE; Ryan ML; Fertig J; Leggio L
Handb Exp Pharmacol; 2018; 248():579-613. PubMed ID: 29294197
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review.
Kranzler HR; Soyka M
JAMA; 2018 Aug; 320(8):815-824. PubMed ID: 30167705
[TBL] [Abstract][Full Text] [Related]
12. SAEM GRACE: Anti-craving medications for alcohol use disorder treatment in the emergency department: A systematic review of direct evidence.
Punia K; Scott W; Manuja K; Sabbineni M; Campbell K; Balodis IM; MacKillop J
Acad Emerg Med; 2024 May; 31(5):504-514. PubMed ID: 37735346
[TBL] [Abstract][Full Text] [Related]
13. Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder.
Burnette EM; Nieto SJ; Grodin EN; Meredith LR; Hurley B; Miotto K; Gillis AJ; Ray LA
Drugs; 2022 Feb; 82(3):251-274. PubMed ID: 35133639
[TBL] [Abstract][Full Text] [Related]
14. Trends in the Use of Naltrexone for Addiction Treatment among Alcohol Use Disorder Admissions in U.S. Substance Use Treatment Facilities.
Qeadan F; Mensah NA; Gu LY; Madden EF; Venner KL; English K
Int J Environ Res Public Health; 2021 Aug; 18(16):. PubMed ID: 34444639
[TBL] [Abstract][Full Text] [Related]
15. Overview of Alcohol Use Disorder.
Kranzler HR
Am J Psychiatry; 2023 Aug; 180(8):565-572. PubMed ID: 37525595
[TBL] [Abstract][Full Text] [Related]
16. Pharmacotherapy for alcohol use disorders - Unequal provision across sociodemographic factors and co-morbid conditions. A cohort study of the total population in Sweden.
Wallhed Finn S; Lundin A; Sjöqvist H; Danielsson AK
Drug Alcohol Depend; 2021 Oct; 227():108964. PubMed ID: 34518028
[TBL] [Abstract][Full Text] [Related]
17. Integration of pharmacotherapy for alcohol use disorder treatment in primary care settings: A scoping review.
Hyland CJ; McDowell MJ; Bain PA; Huskamp HA; Busch AB
J Subst Abuse Treat; 2023 Jan; 144():108919. PubMed ID: 36332528
[TBL] [Abstract][Full Text] [Related]
18. [Meta-analysis of pharmacological therapy with acamprosate, naltrexone, and disulfiram--a systematic review].
Petrov I; Krogh J; Nordentoft M
Ugeskr Laeger; 2011 Nov; 173(48):3103-9. PubMed ID: 22118653
[TBL] [Abstract][Full Text] [Related]
19. Predictors of initiation of and retention on medications for alcohol use disorder among people living with and without HIV.
Oldfield BJ; McGinnis KA; Edelman EJ; Williams EC; Gordon AJ; Akgün K; Crystal S; Fiellin LE; Gaither JR; Goulet JL; Korthuis PT; Marshall BDL; Justice AC; Bryant K; Fiellin DA; Kraemer KL
J Subst Abuse Treat; 2020 Feb; 109():14-22. PubMed ID: 31856946
[TBL] [Abstract][Full Text] [Related]
20. Pharmacotherapies for the Treatment of Alcohol Use Disorders During Pregnancy: Time to Reconsider?
Kelty E; Terplan M; Greenland M; Preen D
Drugs; 2021 May; 81(7):739-748. PubMed ID: 33830479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
